Last updated on February 2020

Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)


Brief description of study

This is a Phase 2, open-label, multicenter study to determine the efficacy and safety of lisocabtagene maraleucel (JCAR017) in adult subjects who have relapsed from, or are refractory to, a single line of immunochemotherapy for aggressive B-cell non-Hodgkin lymphoma (NHL) and are ineligible for hematopoietic stem cell transplant (based on age, performance status, and/or comorbidities). Subjects will receive treatment with lisocabtagene maraleucel and will be followed for 2 years for safety, pharmacokinetics and biomarkers, disease status, quality of life, and survival.

Clinical Study Identifier: NCT03483103

Find a site near you

Start Over

Levine Cancer Institute

Charlotte, NC United States
  Connect »

Regional Cancer Care Associates

East Brunswick, NJ United States
  Connect »

Sutter Medical Center

Sacramento, CA United States
  Connect »

Northwestern University

Chicago, IL United States
  Connect »

Oncology Hematology Care

Cincinnati, OH United States
  Connect »